Pricing Log in Create free account
Saturday 17 October 2026 Export URGN’s income statement to Excel — free account

Urogen Pharma

URGN Healthcare Biotechnology

Urogen Pharma’s revenue for fiscal 2025 (year ended December 2025) was $109.8 million, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 199.2%, EPS grew 73.3%, free cash flow grew 17.3% and total debt rose 56.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

34.56 2.05 −5.60%
Market cap
$1.8B
P/E
0.0×
Fwd P/E
−30.0×
Dividend yield
—
F-score
2/9
Altman Z
−5.16
Beneish M
−1.42
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Urogen Pharma (URGN) Business Profile

Updated before January 2025

Company Overview

UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing innovative solutions for urological and uro-oncological diseases. Founded in 2004, the company is headquartered in Princeton, New Jersey, with research and development operations in Israel. UroGen’s mission is to address unmet medical needs in urology by leveraging its proprietary drug delivery technology and expertise in urological conditions. The company is led by a team of seasoned executives, including Liz Barrett, who serves as the Chief Executive Officer. Barrett brings extensive experience in the pharmaceutical industry, having held leadership roles at companies like Pfizer and Novartis.

Core Business Segments

UroGen Pharma operates primarily in the urology and uro-oncology sectors, with a focus on developing therapies for conditions that currently lack effective treatment options. The company’s core business segments include:

1. Uro-Oncology

UroGen’s flagship product, Jelmyto® (mitomycin), is an innovative treatment for low-grade upper tract urothelial cancer (LG-UTUC). Jelmyto is the first and only FDA-approved non-surgical therapy for this rare and challenging condition. It utilizes UroGen’s proprietary RTGel™ technology, which allows for sustained drug delivery to the urinary tract, improving treatment efficacy.

2. Urological Disorders

UroGen is also developing treatments for other urological conditions, including overactive bladder and interstitial cystitis. The company is exploring the potential of its RTGel™ technology to deliver drugs more effectively to the bladder and other parts of the urinary tract.

3. Pipeline Products

UroGen has a robust pipeline of investigational therapies targeting various urological and uro-oncological conditions. These include:

  • UGN-102: A treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC), currently in Phase 3 clinical trials.
  • UGN-201: An immunotherapy candidate for high-grade bladder cancer.

Business Model

UroGen Pharma’s business model revolves around the development and commercialization of innovative therapies for urological conditions. The company generates revenue primarily through the sale of Jelmyto and aims to expand its revenue streams by bringing additional pipeline products to market. UroGen’s proprietary RTGel™ technology is a key differentiator, enabling the company to develop therapies that address unmet medical needs in urology. The company also collaborates with other pharmaceutical companies to explore new applications for its technology, creating additional revenue opportunities.

Strategic Direction

UroGen Pharma is committed to advancing its pipeline of innovative therapies and expanding its presence in the urology and uro-oncology markets. Key strategic priorities include:

  • Pipeline Advancement: UroGen is focused on completing clinical trials for UGN-102 and other pipeline products, with the goal of securing regulatory approvals and bringing these therapies to market.
  • Geographic Expansion: The company aims to expand the availability of Jelmyto and future products to international markets, leveraging partnerships and collaborations to achieve this goal.
  • Sustainability Goals: UroGen is dedicated to minimizing its environmental impact by adopting sustainable practices in its manufacturing and supply chain operations.
  • Innovation: The company continues to invest in research and development to explore new applications for its RTGel™ technology and identify novel therapeutic targets.

Competitive Landscape

UroGen Pharma operates in a competitive landscape that includes both large pharmaceutical companies and smaller biotechs focused on urology and oncology. Key competitors include:

  • Astellas Pharma: A global pharmaceutical company with a strong presence in urology, offering treatments like Xtandi for prostate cancer.
  • Ferring Pharmaceuticals: Known for its urology portfolio, including treatments for bladder cancer and overactive bladder.
  • Janssen Pharmaceuticals: A division of Johnson & Johnson, with a focus on oncology and urology.
  • Other Biotechs: Smaller companies like Taris Biomedical and Urovant Sciences are also developing innovative therapies for urological conditions.

Risk Factors

UroGen Pharma faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on the success of Jelmyto for revenue generation. Any decline in sales or competition from alternative therapies could adversely affect its financial performance.
  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for pipeline products could hinder the company’s growth prospects.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers exposes UroGen to potential supply chain disruptions.
  • Competition: The entry of new competitors or the development of alternative therapies could erode UroGen’s market share.
  • Financial Risks: As a relatively small biopharmaceutical company, UroGen may face challenges in securing the funding needed to advance its pipeline and achieve its strategic goals.

Recent Developments

UroGen Pharma has made significant progress in recent years, including:

  • Jelmyto Commercialization: The company has successfully launched Jelmyto in the U.S. and continues to expand its market penetration.
  • Clinical Trials: UroGen is advancing its Phase 3 clinical trial for UGN-102, with promising interim results suggesting its potential as a non-surgical treatment for NMIBC.
  • Partnerships: The company has entered into collaborations with other pharmaceutical companies to explore new applications for its RTGel™ technology.
  • COVID-19 Impact: Like many companies, UroGen faced challenges during the COVID-19 pandemic, including disruptions to clinical trials and supply chains. However, the company has demonstrated resilience and is now focused on accelerating its growth.

Investment Considerations

Investors considering UroGen Pharma should weigh the following strengths and risks:

Strengths

  • Innovative Technology: UroGen’s proprietary RTGel™ technology is a key differentiator, enabling the development of therapies that address unmet medical needs.
  • Strong Pipeline: The company’s robust pipeline of investigational therapies offers significant growth potential.
  • Market Leadership: Jelmyto is the first and only FDA-approved non-surgical treatment for LG-UTUC, giving UroGen a competitive edge.
  • Experienced Leadership: The company’s management team brings extensive industry experience and a proven track record of success.

Risks

  • Market Dependence: Heavy reliance on Jelmyto for revenue generation poses a risk if sales decline or competition increases.
  • Regulatory Uncertainty: Delays or failures in obtaining regulatory approvals for pipeline products could impact growth.
  • Financial Challenges: As a smaller biopharmaceutical company, UroGen may face funding challenges.

Conclusion

UroGen Pharma is a pioneering biopharmaceutical company with a strong focus on addressing unmet medical needs in urology and uro-oncology. With its innovative RTGel™ technology, a robust pipeline of investigational therapies, and a commitment to sustainability and innovation, UroGen is well-positioned for future growth. However, investors should carefully consider the risks associated with the company’s reliance on Jelmyto and the challenges of operating in a competitive and highly regulated industry. Overall, UroGen Pharma represents a compelling investment opportunity for those seeking exposure to the biopharmaceutical sector.